EyePoint (EYPT) Liabilities and Shareholders Equity (2011 - 2026)
EyePoint (EYPT) posted Liabilities and Shareholders Equity of $288.2 million for Q1 2026, down 20.82% sequentially from $364.0 million in Q4 2025, and down 20.51% YoY from $362.6 million in Q1 2025.
Analysis
EyePoint (EYPT) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
EyePoint has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $288.2 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 20.51% year-over-year to $288.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 14.3% YoY) and the FY2025 annual result came in at $364.0 million, down 13.02% from the prior year.
- Liabilities and Shareholders Equity fell to $288.2 million in Q1 2026 per EYPT's latest filing, from $364.0 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $418.5 million in Q4 2024 and troughed at $154.6 million in Q1 2023.
- A 5-year average of $274.4 million and a median of $288.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 36.79% in 2023, then soared 112.98% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $180.4 million in 2022, then jumped by 96.93% to $355.2 million in 2023, then climbed by 17.82% to $418.5 million in 2024, then retreated by 13.02% to $364.0 million in 2025, then declined by 20.82% to $288.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $288.2 million, $364.0 million, and $251.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 228.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 228.19 Mn |
| Mar 31, 2026 | 288.22 Mn |
| Dec 31, 2025 | 364.00 Mn |
| Sep 30, 2025 | 251.70 Mn |
| Jun 30, 2025 | 301.15 Mn |
| Mar 31, 2025 | 362.56 Mn |
| Dec 31, 2024 | 418.47 Mn |
| Sep 30, 2024 | 300.92 Mn |
| Jun 30, 2024 | 324.25 Mn |
| Mar 31, 2024 | 329.25 Mn |
| Dec 31, 2023 | 355.18 Mn |
| Sep 30, 2023 | 160.04 Mn |
| Jun 30, 2023 | 175.66 Mn |
| Mar 31, 2023 | 154.59 Mn |
| Dec 31, 2022 | 180.36 Mn |
| Sep 30, 2022 | 220.49 Mn |
| Jun 30, 2022 | 233.43 Mn |
| Mar 31, 2022 | 244.56 Mn |
| Dec 31, 2021 | 263.37 Mn |
| Sep 30, 2021 | 168.25 Mn |